NCT05620836 (STOP-HS2) is a Phase 3 clinical trial of Povorcitinib in Hidradenitis Suppurativa (HS), sponsored by Incyte Corporation.

Who is sponsoring NCT05620836?

NCT05620836 is sponsored by Incyte Corporation.

What drugs are being tested in NCT05620836?

Interventions in NCT05620836: Povorcitinib, Placebo.

What condition does NCT05620836 study?

NCT05620836 studies Hidradenitis Suppurativa (HS).

Is NCT05620836 still recruiting?

NCT05620836 is currently completed. Last updated 9 January 2026.

Last reviewed 2026-01-09 · How we verify

NCT05620836: STOP-HS2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

Completed Phase 3 Last updated 9 January 2026

What this trial tests

Phase 3 trial testing Povorcitinib in Hidradenitis Suppurativa (HS) in 619 participants. Completed in 21 November 2025.

Timeline

22 February 2023

Primary endpoint
7 January 2025

21 November 2025

Quick facts

Lead sponsor	Incyte Corporation
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	619
Start date	22 February 2023
Primary completion	7 January 2025
Estimated completion	21 November 2025
Sites	101 locations across Denmark, France, Italy, United Kingdom, Germany, Poland, Canada, Bulgaria

Drugs / interventions tested

Povorcitinib — full drug profile →
Placebo

Conditions studied

Hidradenitis Suppurativa (HS) — all drugs for Hidradenitis Suppurativa (HS) →

Sponsor

Incyte Corporation — full company profile →

Who can join

18 and older, any sex, with Hidradenitis Suppurativa (HS). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

The Current Clinical Trial Landscape for Hidradenitis Suppurativa: A Narrative Review.
Hunt A, Qian V, Olds H, Daveluy S. · · 2023 · cited 10× · PMID 37261652 · DOI 10.1007/s13555-023-00935-x
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.
Fragoso NM, Masson R, Gillenwater TJ, Shi VY, et al · · 2023 · cited 9× · PMID 37402031 · DOI 10.1007/s13555-023-00956-6
Current Treatments and Future Directions for Hidradenitis Suppurativa: a Narrative Review of Completed and Ongoing Phase 3 Clinical Trials of Biologic Therapies.
Garg A, Hsiao J, Porter ML, Shi V. · · 2025 · cited 3× · PMID 40681937 · DOI 10.1007/s13555-025-01487-y
Dual Targeted Therapy for Hidradenitis Suppurativa: A Narrative Review.
Kherallah K, Chung CS, Ghanshani R, Charrow A, et al · · 2026 · PMID 41276757 · DOI 10.1007/s13555-025-01601-0
Towards a Paradigm Shift in Delivering Hidradenitis Suppurativa Care: a Narrative Review.
Bechara FG, Marzano AV, Martorell A, van der Zee HH, et al · · 2025 · PMID 40583084 · DOI 10.1007/s13555-025-01462-7

Verify or expand the search:

Other trials of Povorcitinib

Trials testing the same drug.

NCT07213973 — Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis S · Phase 2 · recruiting
NCT06516952 — A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) · Phase 3 · recruiting
NCT06516965 — A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) · Phase 3 · active not recruiting
NCT06505265 — A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healt · Phase 1 · completed
NCT06441318 — A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants · Phase 1 · completed

Other recruiting trials for Hidradenitis Suppurativa (HS)

Currently open trials in the same condition.

NCT07213973 — Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis S · Phase 2 · recruiting
NCT07287644 — A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa · Phase 2, PHASE3 · recruiting
NCT07155239 — 1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa) · Phase 1 · recruiting
NCT07021495 — SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) · recruiting
NCT07109765 — Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa · recruiting

Other Incyte Corporation trials

Trials by the same sponsor.

NCT07124078 — A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Di · Phase 2 · recruiting
NCT07441694 — Study of INCA036978 in Participants With Myeloproliferative Neoplasms · Phase 1 · recruiting
NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting
NCT07284849 — A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 i · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05620836 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Incyte Corporation
Last refreshed: 9 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05620836.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing